A team driven by a singular mission

Founder of Avipero Ltd and Avipero Bio, and previously a principal investigator at Edinburgh University with a long-standing interest in tissue repair. She is the principal inventor of the concept of beta1 integrin's role in tissue repair and senescence.

Over 30 years of international leadership experience across biotechnology, global health and medical research. Experienced in building start-ups (2 in biotech). He also sits on the Audit Committee of the EDCTP, a €2 Billion public-public partnership for Global Health research between Europe and Africa.

President of Proventus Consulting. Experienced oncology product development, brand positioning and differentiation and marketing pharmaceutical executive at Eli-Lilly such as ALIMTA® (pemetrexed), GEMZAR® (gemcitabine) and VERZENIO® (abemaciclib).

Global Head of Business Development & Licensing and Mergers & Acquisitions at Sandoz AG. Previously Vice President of Business Development and Alliance Management at HIKMA Pharmaceuticals and Senior Director of Marketing Analytics and Business Insight at Abbott Laboratories.

A seasoned biopharmaceutical executive and clinical development leader with over 25 years of experience advancing innovative therapies from discovery through global regulatory approval. Currently serves as CEO & President of Vaderis Therapeutics. Past roles include co-founder and former COO of Phathom Pharmaceuticals, Entrepreneur-in-Residence at Frazier Life Sciences, and senior positions at Takeda Pharmaceuticals and Abbott Laboratories.

A partner at WG Partners with over 25 years experience of leading corporate transactions. Held senior positions at ABN AMRO, Merrill Lynch European Healthcare Equity Research, and Sudbrook Associates.

An accomplished life sciences executive with three decades of experience commercialising proprietary drug discovery platforms within the Contract Research sector. In August 2026, he founded and became Chief Executive Officer of NBIO Consulting in Oxford, leveraging a career that began in research and development as the UK Head of Research for Whatman Bioscience. Before establishing his consulting practice, he served as the Chief Executive Officer of Orbit Discovery, a biopharmaceutical company specialising in peptide therapeutics. His extensive experience covers the development of multiple antibodies, using cutting edge technology platforms. His leadership background also includes roles as Chief Business Officer and board member at IONTAS, where he navigated the company's acquisition by FairJourney Biologics, and Head of Business Development at Antitope and Abzena, where he was part of the executive team that managed an AIM market listing and multiple corporate acquisitions.